RT Book, Section A1 O’Donnell, James M. A1 Bies, Robert R. A1 Shelton, Richard C. A2 Brunton, Laurence L. A2 Hilal-Dandan, Randa A2 Knollmann, Björn C. SR Print(0) ID 1162535267 T1 Drug Therapy of Depression and Anxiety Disorders T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9781259584732 LK hemonc.mhmedical.com/content.aspx?aid=1162535267 RD 2024/03/28 AB Depression and anxiety disorders are the most common mental illnesses, each affecting in excess of 15% of the population at some point in the life span. With the advent of more selective and safer drugs, the use of antidepressants and anxiolytics has moved from the exclusive domain of psychiatry to other medical specialties, including primary care. The relative safety of the majority of commonly used antidepressants and anxiolytics notwithstanding, their optimal use requires a clear understanding of their mechanisms of action, pharmacokinetics, adverse effects, potential drug interactions, and the differential diagnosis of psychiatric illnesses (Thronson and Pagalilauan, 2014).